Loading data for AIM — first visit, this takes a few seconds.

AIM ImmunoTech Inc. (AIM)

NYSE American: AIM · 即時價格 · USD

0.24

+0.01 (4.35%)

收盤價： Sep 10, 2026, 8:00 PM

0.22

-3.70%

盤後: 7:52 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	0
市值	8.06M
營收 (ttm)	95K
淨利（ttm）	-14.3M
	1.19
	-0.71
	n/a
	-0.61
P/B (ttm)	0.85
P/S (ttm)	84.81
財報日期	n/a

賣價	0.22
成交量	37,825,548
20 日平均成交量	6,548,753
開盤價	0.24
前收盤價	0.23
當日區間	0.23 - 0.25
52 週範圍	0.19 - 2.89
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 AIM

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, ...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Jul 12, 1996

員工 19

證券交易所 NYSE American

股票代號 AIM

網站 https://aimimmuno.com

完整的公司簡介

財務表現

AIM ImmunoTech 在 2025 年的營收為 88K，較前一年的 170K 減少 -48.24%。淨利為 -13.96M，較前期減少 -19.41%。

財務報表

財報驚奇

AIM ImmunoTech 已於 Aug 7, 2026 公布季度財報：

營收為 $22K 低於預期 $0, 年增 37.50% 成長.
每股盈餘為 -0.43 低於預期 -0.31, 年增 88.32% 成長.

價格為何變動

新聞動態

1 月前 · Zacks

Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical

AIM, HAS, FOX, COR and ISRG make the list of stocks with rising P/E ratios, a screen highlighting companies investors may view as having stronger earnings potential.

1 月前 · Zacks

Bet on 5 Top-Ranked Stocks With Rising P/E

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

2 月前 · Zacks

Bet on 5 Top-Ranked Stocks With Rising P/E for Solid Returns

Rising P/E ratios can signal confidence and momentum. Discover 5 stocks backed by strong earnings growth and upside potential.

3 月前 · Stocktwits

AIM Stock Soars Over 200% As Pancreatic Cancer Trial Hits Enrollment Milestone Early — CEO Sees 'Value-Inflection Period' Ahead

AIM ImmunoTech CEO Thomas K. Equels stated that the company is on track to complete the dosing of Ampligen.

4 月前 · Benzinga

Transcript: Aimia Q1 2026 Earnings Conference Call

On Wednesday, Aimia (TSX:AIM) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-ti...

第 1 頁，共 2 頁

AIM ImmunoTech Inc. (AIM)